BIOLASE, Inc.
BIOLASE, Inc. BIOL Peers
See (BIOL) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIOL | $0.02 | +27.39% | 731.9K | 0.00 | $16.18 | N/A |
| ABT | $137.41 | -0.49% | 239.1B | 17.82 | $7.71 | +1.66% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $104.30 | +0.17% | 154.3B | 75.04 | $1.39 | N/A |
| SYK | $392.25 | +1.50% | 149.9B | 53.08 | $7.39 | +0.84% |
| MDT | $86.01 | -0.09% | 110.2B | 23.82 | $3.61 | +3.25% |
| EW | $76.97 | +1.47% | 45.1B | 31.80 | $2.42 | N/A |
| DXCM | $84.68 | -3.30% | 33.2B | 63.67 | $1.33 | N/A |
| STE | $240.47 | +0.37% | 23.7B | 38.97 | $6.17 | +0.94% |
| PHG | $23.92 | +0.06% | 22.1B | 79.72 | $0.30 | +3.70% |
Stock Comparison
BIOL vs ABT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ABT has a market cap of 239.1B. Regarding current trading prices, BIOL is priced at $0.02, while ABT trades at $137.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ABT's P/E ratio is 17.82. In terms of profitability, BIOL's ROE is +5.47%, compared to ABT's ROE of +0.31%. Regarding short-term risk, BIOL is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BSX-PA Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIOL is priced at $0.02, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIOL's ROE is +5.47%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, BIOL is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BSX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BSX has a market cap of 154.3B. Regarding current trading prices, BIOL is priced at $0.02, while BSX trades at $104.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BSX's P/E ratio is 75.04. In terms of profitability, BIOL's ROE is +5.47%, compared to BSX's ROE of +0.10%. Regarding short-term risk, BIOL is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SYK Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SYK has a market cap of 149.9B. Regarding current trading prices, BIOL is priced at $0.02, while SYK trades at $392.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SYK's P/E ratio is 53.08. In terms of profitability, BIOL's ROE is +5.47%, compared to SYK's ROE of +0.11%. Regarding short-term risk, BIOL is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs MDT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, MDT has a market cap of 110.2B. Regarding current trading prices, BIOL is priced at $0.02, while MDT trades at $86.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas MDT's P/E ratio is 23.82. In terms of profitability, BIOL's ROE is +5.47%, compared to MDT's ROE of +0.10%. Regarding short-term risk, BIOL is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs EW Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, EW has a market cap of 45.1B. Regarding current trading prices, BIOL is priced at $0.02, while EW trades at $76.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas EW's P/E ratio is 31.80. In terms of profitability, BIOL's ROE is +5.47%, compared to EW's ROE of +0.49%. Regarding short-term risk, BIOL is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs DXCM Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, DXCM has a market cap of 33.2B. Regarding current trading prices, BIOL is priced at $0.02, while DXCM trades at $84.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas DXCM's P/E ratio is 63.67. In terms of profitability, BIOL's ROE is +5.47%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, BIOL is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs STE Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, STE has a market cap of 23.7B. Regarding current trading prices, BIOL is priced at $0.02, while STE trades at $240.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas STE's P/E ratio is 38.97. In terms of profitability, BIOL's ROE is +5.47%, compared to STE's ROE of +0.09%. Regarding short-term risk, BIOL is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs PHG Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, PHG has a market cap of 22.1B. Regarding current trading prices, BIOL is priced at $0.02, while PHG trades at $23.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas PHG's P/E ratio is 79.72. In terms of profitability, BIOL's ROE is +5.47%, compared to PHG's ROE of +0.03%. Regarding short-term risk, BIOL is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs PODD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, PODD has a market cap of 21.6B. Regarding current trading prices, BIOL is priced at $0.02, while PODD trades at $306.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas PODD's P/E ratio is 55.18. In terms of profitability, BIOL's ROE is +5.47%, compared to PODD's ROE of +0.35%. Regarding short-term risk, BIOL is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ZBH Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ZBH has a market cap of 18.4B. Regarding current trading prices, BIOL is priced at $0.02, while ZBH trades at $92.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ZBH's P/E ratio is 20.62. In terms of profitability, BIOL's ROE is +5.47%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, BIOL is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ABMD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIOL is priced at $0.02, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIOL's ROE is +5.47%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIOL is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ALGN Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ALGN has a market cap of 13.6B. Regarding current trading prices, BIOL is priced at $0.02, while ALGN trades at $187.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ALGN's P/E ratio is 33.97. In terms of profitability, BIOL's ROE is +5.47%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, BIOL is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SNN Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, BIOL is priced at $0.02, while SNN trades at $29.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SNN's P/E ratio is 31.81. In terms of profitability, BIOL's ROE is +5.47%, compared to SNN's ROE of +0.08%. Regarding short-term risk, BIOL is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SWAV Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIOL is priced at $0.02, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIOL's ROE is +5.47%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, BIOL is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs PEN Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, PEN has a market cap of 9.8B. Regarding current trading prices, BIOL is priced at $0.02, while PEN trades at $253.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas PEN's P/E ratio is 234.39. In terms of profitability, BIOL's ROE is +5.47%, compared to PEN's ROE of +0.04%. Regarding short-term risk, BIOL is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs GMED Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, GMED has a market cap of 7.9B. Regarding current trading prices, BIOL is priced at $0.02, while GMED trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas GMED's P/E ratio is 43.43. In terms of profitability, BIOL's ROE is +5.47%, compared to GMED's ROE of +0.05%. Regarding short-term risk, BIOL is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BIO-B Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, BIOL is priced at $0.02, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, BIOL's ROE is +5.47%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, BIOL is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BIO Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BIO has a market cap of 6.6B. Regarding current trading prices, BIOL is priced at $0.02, while BIO trades at $240.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BIO's P/E ratio is -3.15. In terms of profitability, BIOL's ROE is +5.47%, compared to BIO's ROE of -0.32%. Regarding short-term risk, BIOL is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BRKR Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BRKR has a market cap of 6.2B. Regarding current trading prices, BIOL is priced at $0.02, while BRKR trades at $40.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BRKR's P/E ratio is 78.71. In terms of profitability, BIOL's ROE is +5.47%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, BIOL is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs GKOS Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, GKOS has a market cap of 5.7B. Regarding current trading prices, BIOL is priced at $0.02, while GKOS trades at $99.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas GKOS's P/E ratio is -43.75. In terms of profitability, BIOL's ROE is +5.47%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, BIOL is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs IRTC Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, IRTC has a market cap of 4.8B. Regarding current trading prices, BIOL is priced at $0.02, while IRTC trades at $151.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas IRTC's P/E ratio is -48.53. In terms of profitability, BIOL's ROE is +5.47%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, BIOL is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs NARI Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIOL is priced at $0.02, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIOL's ROE is +5.47%, compared to NARI's ROE of -0.18%. Regarding short-term risk, BIOL is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs TMDX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, TMDX has a market cap of 4.4B. Regarding current trading prices, BIOL is priced at $0.02, while TMDX trades at $128.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas TMDX's P/E ratio is 90.55. In terms of profitability, BIOL's ROE is +5.47%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, BIOL is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ITGR Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, BIOL is priced at $0.02, while ITGR trades at $120.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ITGR's P/E ratio is 56.20. In terms of profitability, BIOL's ROE is +5.47%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, BIOL is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs INSP Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, INSP has a market cap of 3.9B. Regarding current trading prices, BIOL is priced at $0.02, while INSP trades at $131.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas INSP's P/E ratio is 60.23. In terms of profitability, BIOL's ROE is +5.47%, compared to INSP's ROE of +0.10%. Regarding short-term risk, BIOL is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs AXNX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, BIOL is priced at $0.02, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas AXNX's P/E ratio is -709.80. In terms of profitability, BIOL's ROE is +5.47%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, BIOL is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs PRCT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, BIOL is priced at $0.02, while PRCT trades at $58.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas PRCT's P/E ratio is -34.45. In terms of profitability, BIOL's ROE is +5.47%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, BIOL is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs LIVN Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, LIVN has a market cap of 2.5B. Regarding current trading prices, BIOL is priced at $0.02, while LIVN trades at $45.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas LIVN's P/E ratio is -11.27. In terms of profitability, BIOL's ROE is +5.47%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, BIOL is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs NUVA Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIOL is priced at $0.02, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIOL's ROE is +5.47%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIOL is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs UFPT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, BIOL is priced at $0.02, while UFPT trades at $246.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas UFPT's P/E ratio is 30.26. In terms of profitability, BIOL's ROE is +5.47%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, BIOL is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ATEC Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, BIOL is priced at $0.02, while ATEC trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ATEC's P/E ratio is -9.87. In terms of profitability, BIOL's ROE is +5.47%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, BIOL is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CNMD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, BIOL is priced at $0.02, while CNMD trades at $52.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CNMD's P/E ratio is 13.75. In terms of profitability, BIOL's ROE is +5.47%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, BIOL is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs HSKA Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIOL is priced at $0.02, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIOL's ROE is +5.47%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIOL is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs AORT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, BIOL is priced at $0.02, while AORT trades at $30.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas AORT's P/E ratio is -59.96. In terms of profitability, BIOL's ROE is +5.47%, compared to AORT's ROE of -0.07%. Regarding short-term risk, BIOL is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs TNDM Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, BIOL is priced at $0.02, while TNDM trades at $19.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas TNDM's P/E ratio is -6.96. In terms of profitability, BIOL's ROE is +5.47%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, BIOL is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs AHCO Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, BIOL is priced at $0.02, while AHCO trades at $9.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas AHCO's P/E ratio is 15.54. In terms of profitability, BIOL's ROE is +5.47%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, BIOL is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SSII Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SSII has a market cap of 1.1B. Regarding current trading prices, BIOL is priced at $0.02, while SSII trades at $5.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SSII's P/E ratio is -73.75. In terms of profitability, BIOL's ROE is +5.47%, compared to SSII's ROE of -1.33%. Regarding short-term risk, BIOL is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SILK Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIOL is priced at $0.02, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIOL's ROE is +5.47%, compared to SILK's ROE of -0.29%. Regarding short-term risk, BIOL is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs FNA Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIOL is priced at $0.02, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIOL's ROE is +5.47%, compared to FNA's ROE of -0.36%. Regarding short-term risk, BIOL is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ESTA Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ESTA has a market cap of 1.1B. Regarding current trading prices, BIOL is priced at $0.02, while ESTA trades at $37.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ESTA's P/E ratio is -12.01. In terms of profitability, BIOL's ROE is +5.47%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, BIOL is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs INMD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, INMD has a market cap of 987.7M. Regarding current trading prices, BIOL is priced at $0.02, while INMD trades at $14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas INMD's P/E ratio is 6.37. In terms of profitability, BIOL's ROE is +5.47%, compared to INMD's ROE of +0.25%. Regarding short-term risk, BIOL is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs IART Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, IART has a market cap of 922.4M. Regarding current trading prices, BIOL is priced at $0.02, while IART trades at $11.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas IART's P/E ratio is -31.24. In terms of profitability, BIOL's ROE is +5.47%, compared to IART's ROE of -0.03%. Regarding short-term risk, BIOL is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CSII Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIOL is priced at $0.02, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIOL's ROE is +5.47%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIOL is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs IRMD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, IRMD has a market cap of 768M. Regarding current trading prices, BIOL is priced at $0.02, while IRMD trades at $60.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas IRMD's P/E ratio is 38.97. In terms of profitability, BIOL's ROE is +5.47%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BIOL is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SIBN Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SIBN has a market cap of 763.7M. Regarding current trading prices, BIOL is priced at $0.02, while SIBN trades at $17.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SIBN's P/E ratio is -28.44. In terms of profitability, BIOL's ROE is +5.47%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, BIOL is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CRY Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, BIOL is priced at $0.02, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CRY's P/E ratio is 425.71. In terms of profitability, BIOL's ROE is +5.47%, compared to CRY's ROE of -0.07%. Regarding short-term risk, BIOL is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CBLL Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CBLL has a market cap of 697.6M. Regarding current trading prices, BIOL is priced at $0.02, while CBLL trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CBLL's P/E ratio is -15.44. In terms of profitability, BIOL's ROE is +5.47%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, BIOL is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs APEN Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIOL is priced at $0.02, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIOL's ROE is +5.47%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIOL is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs AVNS Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, AVNS has a market cap of 567.6M. Regarding current trading prices, BIOL is priced at $0.02, while AVNS trades at $12.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas AVNS's P/E ratio is -1.48. In terms of profitability, BIOL's ROE is +5.47%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, BIOL is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BFLY-WT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BFLY-WT has a market cap of 561.7M. Regarding current trading prices, BIOL is priced at $0.02, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, BIOL's ROE is +5.47%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, BIOL is more volatile compared to BFLY-WT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs RXST Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, RXST has a market cap of 535.6M. Regarding current trading prices, BIOL is priced at $0.02, while RXST trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas RXST's P/E ratio is -19.97. In terms of profitability, BIOL's ROE is +5.47%, compared to RXST's ROE of -0.10%. Regarding short-term risk, BIOL is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs KIDS Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, KIDS has a market cap of 535.5M. Regarding current trading prices, BIOL is priced at $0.02, while KIDS trades at $21.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas KIDS's P/E ratio is -12.28. In terms of profitability, BIOL's ROE is +5.47%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, BIOL is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BFLY Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BFLY has a market cap of 488.4M. Regarding current trading prices, BIOL is priced at $0.02, while BFLY trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BFLY's P/E ratio is -6.58. In terms of profitability, BIOL's ROE is +5.47%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, BIOL is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs AXGN Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, AXGN has a market cap of 466.8M. Regarding current trading prices, BIOL is priced at $0.02, while AXGN trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas AXGN's P/E ratio is -64.06. In terms of profitability, BIOL's ROE is +5.47%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, BIOL is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SMLR Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SMLR has a market cap of 457.7M. Regarding current trading prices, BIOL is priced at $0.02, while SMLR trades at $41.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SMLR's P/E ratio is -17.17. In terms of profitability, BIOL's ROE is +5.47%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, BIOL is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BVS Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BVS has a market cap of 443.6M. Regarding current trading prices, BIOL is priced at $0.02, while BVS trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BVS's P/E ratio is -13.93. In terms of profitability, BIOL's ROE is +5.47%, compared to BVS's ROE of -0.21%. Regarding short-term risk, BIOL is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs OFIX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, OFIX has a market cap of 425.7M. Regarding current trading prices, BIOL is priced at $0.02, while OFIX trades at $10.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas OFIX's P/E ratio is -2.94. In terms of profitability, BIOL's ROE is +5.47%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, BIOL is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CTKB Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CTKB has a market cap of 421.8M. Regarding current trading prices, BIOL is priced at $0.02, while CTKB trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CTKB's P/E ratio is -37.00. In terms of profitability, BIOL's ROE is +5.47%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, BIOL is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SRDX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SRDX has a market cap of 413.4M. Regarding current trading prices, BIOL is priced at $0.02, while SRDX trades at $28.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SRDX's P/E ratio is -20.65. In terms of profitability, BIOL's ROE is +5.47%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, BIOL is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SENS Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SENS has a market cap of 376.8M. Regarding current trading prices, BIOL is priced at $0.02, while SENS trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SENS's P/E ratio is -4.54. In terms of profitability, BIOL's ROE is +5.47%, compared to SENS's ROE of -7.46%. Regarding short-term risk, BIOL is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs TMCI Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, TMCI has a market cap of 375.5M. Regarding current trading prices, BIOL is priced at $0.02, while TMCI trades at $5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas TMCI's P/E ratio is -7.02. In terms of profitability, BIOL's ROE is +5.47%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, BIOL is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs PACB Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, PACB has a market cap of 366.1M. Regarding current trading prices, BIOL is priced at $0.02, while PACB trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas PACB's P/E ratio is -0.45. In terms of profitability, BIOL's ROE is +5.47%, compared to PACB's ROE of -1.70%. Regarding short-term risk, BIOL is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs NPCE Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, NPCE has a market cap of 346.7M. Regarding current trading prices, BIOL is priced at $0.02, while NPCE trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas NPCE's P/E ratio is -12.89. In terms of profitability, BIOL's ROE is +5.47%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, BIOL is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs OM Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, OM has a market cap of 346.6M. Regarding current trading prices, BIOL is priced at $0.02, while OM trades at $19.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas OM's P/E ratio is -0.68. In terms of profitability, BIOL's ROE is +5.47%, compared to OM's ROE of -1.45%. Regarding short-term risk, BIOL is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs VREX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, VREX has a market cap of 337.4M. Regarding current trading prices, BIOL is priced at $0.02, while VREX trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas VREX's P/E ratio is -7.89. In terms of profitability, BIOL's ROE is +5.47%, compared to VREX's ROE of -0.08%. Regarding short-term risk, BIOL is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs NNOX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, NNOX has a market cap of 334.8M. Regarding current trading prices, BIOL is priced at $0.02, while NNOX trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas NNOX's P/E ratio is -5.77. In terms of profitability, BIOL's ROE is +5.47%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, BIOL is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CLPT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CLPT has a market cap of 332.4M. Regarding current trading prices, BIOL is priced at $0.02, while CLPT trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CLPT's P/E ratio is -15.47. In terms of profitability, BIOL's ROE is +5.47%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, BIOL is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CATX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CATX has a market cap of 282.1M. Regarding current trading prices, BIOL is priced at $0.02, while CATX trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CATX's P/E ratio is -3.09. In terms of profitability, BIOL's ROE is +5.47%, compared to CATX's ROE of -0.27%. Regarding short-term risk, BIOL is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SNWV Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SNWV has a market cap of 281.5M. Regarding current trading prices, BIOL is priced at $0.02, while SNWV trades at $32.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SNWV's P/E ratio is -5.28. In terms of profitability, BIOL's ROE is +5.47%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, BIOL is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs VMD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, VMD has a market cap of 275.9M. Regarding current trading prices, BIOL is priced at $0.02, while VMD trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas VMD's P/E ratio is 23.27. In terms of profitability, BIOL's ROE is +5.47%, compared to VMD's ROE of +0.10%. Regarding short-term risk, BIOL is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CERS Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CERS has a market cap of 252.3M. Regarding current trading prices, BIOL is priced at $0.02, while CERS trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CERS's P/E ratio is -13.20. In terms of profitability, BIOL's ROE is +5.47%, compared to CERS's ROE of -0.35%. Regarding short-term risk, BIOL is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ZIMV Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ZIMV has a market cap of 250.2M. Regarding current trading prices, BIOL is priced at $0.02, while ZIMV trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ZIMV's P/E ratio is -9.96. In terms of profitability, BIOL's ROE is +5.47%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, BIOL is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs PTHL Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, PTHL has a market cap of 243.4M. Regarding current trading prices, BIOL is priced at $0.02, while PTHL trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas PTHL's P/E ratio is -341.60. In terms of profitability, BIOL's ROE is +5.47%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, BIOL is more volatile compared to PTHL. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs MASS Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, MASS has a market cap of 243.1M. Regarding current trading prices, BIOL is priced at $0.02, while MASS trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas MASS's P/E ratio is -3.05. In terms of profitability, BIOL's ROE is +5.47%, compared to MASS's ROE of -0.13%. Regarding short-term risk, BIOL is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs QTRX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, QTRX has a market cap of 240.9M. Regarding current trading prices, BIOL is priced at $0.02, while QTRX trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas QTRX's P/E ratio is -5.00. In terms of profitability, BIOL's ROE is +5.47%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, BIOL is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs TCMD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, TCMD has a market cap of 239.9M. Regarding current trading prices, BIOL is priced at $0.02, while TCMD trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas TCMD's P/E ratio is 15.64. In terms of profitability, BIOL's ROE is +5.47%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, BIOL is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BDMD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BDMD has a market cap of 237.2M. Regarding current trading prices, BIOL is priced at $0.02, while BDMD trades at $6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BDMD's P/E ratio is 13.55. In terms of profitability, BIOL's ROE is +5.47%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, BIOL is more volatile compared to BDMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs MXCT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, MXCT has a market cap of 237.1M. Regarding current trading prices, BIOL is priced at $0.02, while MXCT trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas MXCT's P/E ratio is -5.57. In terms of profitability, BIOL's ROE is +5.47%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, BIOL is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BWAY Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BWAY has a market cap of 233.9M. Regarding current trading prices, BIOL is priced at $0.02, while BWAY trades at $12.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BWAY's P/E ratio is 56.27. In terms of profitability, BIOL's ROE is +5.47%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, BIOL is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs NVRO Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIOL is priced at $0.02, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIOL's ROE is +5.47%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BIOL is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs BSGM Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, BSGM has a market cap of 220.7M. Regarding current trading prices, BIOL is priced at $0.02, while BSGM trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas BSGM's P/E ratio is -15.25. In terms of profitability, BIOL's ROE is +5.47%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, BIOL is more volatile compared to BSGM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs SGHT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, SGHT has a market cap of 218.2M. Regarding current trading prices, BIOL is priced at $0.02, while SGHT trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas SGHT's P/E ratio is -4.31. In terms of profitability, BIOL's ROE is +5.47%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, BIOL is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs EYES Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, EYES has a market cap of 210M. Regarding current trading prices, BIOL is priced at $0.02, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas EYES's P/E ratio is N/A. In terms of profitability, BIOL's ROE is +5.47%, compared to EYES's ROE of -0.26%. Regarding short-term risk, BIOL is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs TLSI Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, TLSI has a market cap of 197.9M. Regarding current trading prices, BIOL is priced at $0.02, while TLSI trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas TLSI's P/E ratio is -4.74. In terms of profitability, BIOL's ROE is +5.47%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, BIOL is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs INGN Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, INGN has a market cap of 191.2M. Regarding current trading prices, BIOL is priced at $0.02, while INGN trades at $7.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas INGN's P/E ratio is -6.18. In terms of profitability, BIOL's ROE is +5.47%, compared to INGN's ROE of -0.15%. Regarding short-term risk, BIOL is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ELMD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ELMD has a market cap of 183.1M. Regarding current trading prices, BIOL is priced at $0.02, while ELMD trades at $21.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ELMD's P/E ratio is 27.63. In terms of profitability, BIOL's ROE is +5.47%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, BIOL is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs PROF Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, PROF has a market cap of 180.6M. Regarding current trading prices, BIOL is priced at $0.02, while PROF trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas PROF's P/E ratio is -4.97. In terms of profitability, BIOL's ROE is +5.47%, compared to PROF's ROE of -0.70%. Regarding short-term risk, BIOL is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ANIK Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ANIK has a market cap of 159.1M. Regarding current trading prices, BIOL is priced at $0.02, while ANIK trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ANIK's P/E ratio is -14.79. In terms of profitability, BIOL's ROE is +5.47%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, BIOL is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs CVRX Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, CVRX has a market cap of 152.3M. Regarding current trading prices, BIOL is priced at $0.02, while CVRX trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas CVRX's P/E ratio is -2.73. In terms of profitability, BIOL's ROE is +5.47%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, BIOL is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs RPID Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, RPID has a market cap of 150.3M. Regarding current trading prices, BIOL is priced at $0.02, while RPID trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas RPID's P/E ratio is -3.33. In terms of profitability, BIOL's ROE is +5.47%, compared to RPID's ROE of -0.56%. Regarding short-term risk, BIOL is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs LNSR Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, LNSR has a market cap of 148.8M. Regarding current trading prices, BIOL is priced at $0.02, while LNSR trades at $12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas LNSR's P/E ratio is -2.57. In terms of profitability, BIOL's ROE is +5.47%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, BIOL is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs AVR Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, AVR has a market cap of 148.4M. Regarding current trading prices, BIOL is priced at $0.02, while AVR trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas AVR's P/E ratio is -1.15. In terms of profitability, BIOL's ROE is +5.47%, compared to AVR's ROE of -2.92%. Regarding short-term risk, BIOL is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs RCEL Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, RCEL has a market cap of 126.1M. Regarding current trading prices, BIOL is priced at $0.02, while RCEL trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas RCEL's P/E ratio is -2.18. In terms of profitability, BIOL's ROE is +5.47%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, BIOL is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs LUCD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, LUCD has a market cap of 124.4M. Regarding current trading prices, BIOL is priced at $0.02, while LUCD trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas LUCD's P/E ratio is -0.98. In terms of profitability, BIOL's ROE is +5.47%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, BIOL is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs OWLT Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, OWLT has a market cap of 121.1M. Regarding current trading prices, BIOL is priced at $0.02, while OWLT trades at $7.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas OWLT's P/E ratio is -4.55. In terms of profitability, BIOL's ROE is +5.47%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, BIOL is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs LUNG Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, LUNG has a market cap of 105.9M. Regarding current trading prices, BIOL is priced at $0.02, while LUNG trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas LUNG's P/E ratio is -1.83. In terms of profitability, BIOL's ROE is +5.47%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, BIOL is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs ICAD Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, ICAD has a market cap of 102.6M. Regarding current trading prices, BIOL is priced at $0.02, while ICAD trades at $3.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas ICAD's P/E ratio is -19.66. In terms of profitability, BIOL's ROE is +5.47%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, BIOL is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.
BIOL vs MGRM Comparison
BIOL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOL stands at 731.9K. In comparison, MGRM has a market cap of 102.4M. Regarding current trading prices, BIOL is priced at $0.02, while MGRM trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOL currently has a P/E ratio of 0.00, whereas MGRM's P/E ratio is -5.74. In terms of profitability, BIOL's ROE is +5.47%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, BIOL is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for BIOL.